Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STX-1
- Development stage
- Preclinical
- Lead developer
- StarkAge Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
STX-1 is a first-in-class antibody-drug conjugate (ADC) developed by StarkAge Therapeutics that targets Dipeptidyl peptidase 4 (DPP4), also known as CD26. DPP4 is a transmembrane protein highly overexpressed on senescent cells and certain cancer cells, serving as both a marker of cellular senescence and a tumor-associated antigen. STX-1 is designed to selectively eliminate these cells by delivering a cytotoxic payload, thereby addressing the role of senescent cells in promoting tumor progression and resistance. The program is currently in preclinical development with an initial focus on liver cancer and prostate cancer, progressing toward IND-enabling studies.
- Other names
- StarkAge Therapeutics DPP4-ADCAnti-DPP4 ADCAnti-DPP-4 ADCAnti-DPP 4 ADCCD26-targeted ADCCD-26-targeted ADCCD 26-targeted ADC
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on STX-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STX-1.